The DEA Hearing Is Six Weeks Away. Here's What That Actually Means for Cannabis.

The DEA Hearing Is Six Weeks Away. Here's What That Actually Means for Cannabis.

The clock is now running on one of the most consequential proceedings in American drug policy history. The Drug Enforcement Administration's formal hearing on whether to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act is officially set to begin June 29, 2026, and this week brought the first concrete sign of how contentious that proceeding will be: organizations spanning the full spectrum of opinion on cannabis policy — from legalization advocates to prohibition supporters — filed notices of intent to participate.

NORML, the country's oldest marijuana reform organization, filed its notice this week, arguing that consumers must have representation at the table. Smart Approaches to Marijuana, the leading anti-legalization organization, also filed, signaling its intention to challenge the rescheduling on the merits. The May 28 deadline for notices passed with a large field of participants now locked in, setting the stage for what could be a lengthy and legally complex administrative process.

To understand why this hearing matters — and why the outcome is not as certain as some in the industry would like to believe — it helps to understand the procedural history. The Biden administration initiated the rescheduling process in October 2022, following an HHS recommendation to move marijuana to Schedule III. The DEA eventually scheduled hearings, but those proceedings collapsed after an interlocutory appeal tied up the process in court. Then, in April 2026, Acting Attorney General Todd Blanche issued an order that took two significant actions simultaneously: it immediately placed FDA-approved marijuana products and state-licensed medical marijuana products in Schedule III, and it called for entirely new administrative hearings to consider the broader rescheduling question. The June 29 hearing is the result of that reset.

For operators and patients in states with medical marijuana programs, the partial rescheduling already in effect is real and meaningful. Cannabis sold through state-licensed medical dispensaries no longer has to labor under the full weight of IRS Section 280E, the tax provision that prevented cannabis businesses from deducting ordinary business expenses because they were trafficking in a Schedule I substance. That change is translating into actual money for businesses — though a group of Congressional lawmakers made clear this week that the tax situation remains murky. In a letter to the Treasury Department and IRS, the lawmakers urged swift and clear guidance on exactly how the new rules apply, arguing that uncertainty is itself a business problem. Treasury has not yet responded publicly.

At the state level, the week produced a mixed picture that illustrated both the progress and the persistent fragility of cannabis reform. In Minnesota, Governor Tim Walz signed legislation that streamlines the state's recreational cannabis market and opens pathways for hemp operators to participate in the licensed system — a pragmatic reconciliation of two markets that have long existed in uneasy parallel. The bill also requires the state's regulators to begin developing recommendations for a psilocybin therapy program, signaling Minnesota's intention to be a leader in the broader psychedelic policy conversation.

Virginia offered a more frustrating story. Governor Abigail Spanberger's decision to veto legislation that would have established a regulated adult-use cannabis sales market drew sharp condemnation from advocates who pointed out that Spanberger campaigned in part on cannabis reform. Top Virginia lawmakers are now exploring whether they can attach adult-use sales provisions to budget legislation due by July 1 — a strategy that reflects both the political urgency and the institutional creativity that cannabis reform has always demanded. Whether that workaround survives is unclear; what is clear is that Virginia's estimated 2 million cannabis consumers continue to exist in a gray zone, legally allowed to possess and grow cannabis but without a legal place to buy it.

Louisiana provided another deadline of note. The state had a May 29 crossover deadline for legislation creating a three-year adult-use pilot program to advance to the next legislative chamber. Louisiana's path to any form of legalization has been halting, but a pilot program framing — essentially asking legislators to approve a trial rather than a permanent system — has shown some traction in conservative states wary of a full commitment.

Connecticut, for its part, made a quiet but consequential change to its cannabis tax structure, with Governor Ned Lamont signing legislation converting the state's cannabis tax from a per-THC assessment to a flat 10.75% excise tax. The old THC-based tax created perverse incentives to push lower-potency products, and industry groups had long argued it was economically irrational. The new structure aligns Connecticut with how most mature cannabis markets handle taxation.

Perhaps the most telling policy data point of the week came from polling. A Marijuana Moment/NuggMD quarterly tracking survey found that nearly three out of four cannabis consumers now view the Trump administration favorably on cannabis policy — a striking number that reflects how powerfully the partial rescheduling action has shifted sentiment. Cannabis has long been an issue that scrambles partisan expectations, and the current moment is a vivid illustration of that dynamic.

The next six weeks will determine whether the DEA hearing accelerates full rescheduling or becomes another chapter in the industry's long experience with administrative delay. Either way, the proceedings will shape the regulatory and financial architecture of cannabis for years to come. Those watching closely should prepare for complexity.